Top

Published in:

Open Access 01-12-2009 | Research

Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation

Authors: Joseph McGuirk, Gang Hao, Weijian Hou, Sunil Abhyankar, Casey Williams, Weisi Yan, Jianda Yuan, Xiuqin Guan, Robert Belt, Shaun Dejarnette, Jeffery Wieman, Ying Yan

Published in: Journal of Hematology & Oncology | Issue 1/2009

Abstract

We studied serum proteomic profiling in patients with graft versus host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) by two-dimensional gel electrophoresis (2-DE) and mass spectrometry analysis. The expression of a group of proteins, haptoglobin (Hp), alpha-1-antitrypsin, apolipoprotein A-IV, serum paraoxonase and Zn-alpha-glycoprotein were increased and the proteins, clusterin precursor, alpha-2-macroglobulin, serum amyloid protein precursor, sex hormone-binding globulin, serotransferrin and complement C4 were decreased in patients with extensive chronic GVHD (cGVHD). Serum haptoglobin (Hp) levels in patients with cGVHD were demonstrated to be statistically higher than in patients without cGVHD and normal controls (p < 0.01). We used immunoblotting and PCR in combination with 2-DE gel image analysis to determine Hp polymorphisms in 25 allo-HCT patients and 16 normal donors. The results demonstrate that patients with cGVHD had a higher incidence of HP 2-2 phenotype (43.8%), in comparison to the patients without cGVHD (0%) and normal donors (18.7%), suggesting the possibility that specific Hp polymorphism may play a role in the development of cGVHD after allo-HCT. In this study, quantitative serum Hp levels were shown to be related to cGVHD development. Further, the data suggest the possibility that specific Hp polymorphisms may be associated with cGVHD development and warrant further investigation.

Available only for authorised users

Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med. 2006, 354: 1813-1826. 10.1056/NEJMra052638.CrossRefPubMed

Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM, Aker SN, Salazar RC, McDonald GB: An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006, 108 (2): 749-755. 10.1182/blood-2006-01-0254.PubMedCentralCrossRefPubMed

Deeg HJ, Antin JH: The Clinical Spectrum of Acute Graft-Versus-Host Disease. Semin Hematol. 2006, 43: 24-31. 10.1053/j.seminhematol.2005.09.003.CrossRefPubMed

Vogelsang GB, Hess AD, Berkman AW, Tutschka PJ, Farmer ER, Converse PJ, Santos GW: An in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical bone marrow transplants. N Engl J Med. 1985, 313: 645-650.CrossRefPubMed

Dickinson AM, Sviland L, Wang XN, Jackson G, Taylor PR, Dunn A, Proctor SJ: Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model. Transplantation. 1998, 66: 857-863. 10.1097/00007890-199810150-00008.CrossRefPubMed

Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H: Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med. 1992, 327: 1613-1617.CrossRefPubMed

Wang XN, Taylor PR, Skinner R, Jackson GH, Proctor SJ, Hedley D, Dickinson AM: T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Transplantation. 2000, 70: 488-493. 10.1097/00007890-200008150-00016.CrossRefPubMed

Dickinson AM, Holler E: Polymorphisms of cytokine and innate immunity genes and GVHD. Best Prac & Res Clin Haematol. 2008, 21: 149-164. 10.1016/j.beha.2008.03.004.CrossRef

Rocha V, Franco RF, Porcher R, Bittencourt H, Silva WA, Latouche A, Devergie A, Esperou H, Ribaud P, Socie G, Zago MA, Gluckman E: Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002, 100: 3908-3918. 10.1182/blood-2002-04-1033.CrossRefPubMed

10.

Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG: Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2003, 122 (5): 778-87. 10.1046/j.1365-2141.2003.04510.x.CrossRefPubMed

11.

Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, Hansen JA: Relation of an interleukin-10 promoter polymorphism to graft-versus-Host disease and survival after hematopoietic-Cell transplantation. N Engl J Med. 2003, 349: 2201-10. 10.1056/NEJMoa022060.CrossRefPubMed

12.

Behar E, Chao NJ, Hiraki DD, Krishnaswamy S, Brown BW, Zehnder JL, Grumet FC: Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med. 1996, 334 (5): 286-91. 10.1056/NEJM199602013340502.CrossRefPubMed

13.

Cavet J, Dickinson AM, Norden J, Taylor PRA, Jackson GH, Middleton PG: Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001, 98: 1594-1600. 10.1182/blood.V98.5.1594.CrossRefPubMed

14.

Mateos-Caceres PJ, Garcia-Mendez A, Lopez Farre A, Macaya C, Nunez A, Gomez J, Alonso-Orgaz S, Carrasco C, Burgos ME, de Andres R, Granizo JJ, Farre J, Rico LA: Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol. 2004, 44 (8): 1578-83. 10.1016/j.jacc.2004.06.073.CrossRefPubMed

15.

Hershko AY, Naparstek Y: Autoimmunity in the era of genomics and proteomics. Autoimmun Rev. 2006, 5 (4): 230-233. 10.1016/j.autrev.2005.07.003.CrossRefPubMed

16.

Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H: Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer. 2006, 106 (7): 1587-1594. 10.1002/cncr.21770.CrossRefPubMed

17.

Hudelist G, Singer CF, Pischinger KI, Kaserer K, Manavi M, Kubista E, Czerwenka KF: Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics. 2006, 6 (6): 1989-2002. 10.1002/pmic.200500129.CrossRefPubMed

18.

Wang H, Clouthier SG, Galchev V, Misek DE, Duffner U, Min CK, Zhao R, Tra J, Omenn GS, Ferrara JL, Hanash SM: Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics. 2005, 4 (5): 618-625. 10.1074/mcp.M400126-MCP200.CrossRefPubMed

19.

Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A, Hertenstein B, Mischak H, Weissinger EM: Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood. 2004, 104 (2): 340-349. 10.1182/blood-2004-02-0518.CrossRefPubMed

20.

Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JLM: A biomarker panel for acute graft-versus-host disease. Blood. 2009, 113: 273-278. 10.1182/blood-2008-07-167098.PubMedCentralCrossRefPubMed

21.

Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M, Kolb HJ, Zander A, Zürbig P, Kellmann M, Ganser A: Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007, 109: 5511-5519. 10.1182/blood-2007-01-069757.CrossRefPubMed

22.

Hori T, Naishiro Y, Sohma H, Suzuki N, Hatakeyama N, Yamamoto M, Sonoda T, Mizue Y, Imai K, Tsutsumi H, Kokai Y: CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood. 2008, 111: 4403-4412. 10.1182/blood-2007-06-097287.PubMedCentralCrossRefPubMed

23.

Westereier R: Electrophoresis in practice. Part II. 2001, WILEY-VCH, 123-286.

24.

Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, Kastrati A: Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem. 2002, 48 (9): 1377-82.PubMed

25.

Beutler E, Gelbart T, Lee P: haptoglobin polymorphism and iron homeostasis. Clin Chem. 2002, 48: 2232-2235.PubMed

26.

Sadrzadeh SMH, Bozorgmehr J: Haptoglobin phenotypes in health and disorders. Am J Clin Pathol. 2004, 121 Suppl: S97-S104.PubMed

27.

Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D, Quezado M, Kleine D, Rucker S, Espina V, Whiteley G, Liotta L, Petricoin E, Pittaluga E, Hitt B, Barrett AJ, Rosenblattc K, Childs RW: Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Expe Hematol. 2006, 34: 796-801. 10.1016/j.exphem.2006.02.013.CrossRef

28.

Baumann H, Gauldie J: The acute phase response. Immunol Today. 1994, 15: 74-80. 10.1016/0167-5699(94)90137-6.CrossRefPubMed

29.

Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999, 340: 448-454. 10.1056/NEJM199902113400607.CrossRefPubMed

30.

Wang Y, Kinzie E, Berger FG, Lim SK, Baumann H: Haptoglobin, an inflammation-inducible plasma protein. Redox Rep. 2001, 6: 379-385. 10.1179/135100001101536580.CrossRefPubMed

31.

Harvey SB, Zhang Y, Wilson-Grady J, Monkkonen T, Nelsestuen JL, Kasthuri JS, Verneris MR, Lund TC, Ely EW, GR Bernard, Zeisler H, Homoncik M, Jilma B, Swan T, Kellogg TA: O-Glycoside Biomarker of Apolipoprotein C3: Responsiveness to Obesity, Bariatric Surgery, and Therapy with Metformin, to Chronic or Severe Liver Disease and to Mortality in Severe Sepsis and Graft vs Host Disease. J Proteome Res. 2009, 8: 603-612. 10.1021/pr800751x.CrossRefPubMed

32.

Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lämmle B, Moake JL, Richardson P, Socié G, Zeigler Z, Niederwieser D, Barbui T: Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007, 92: 95-100. 10.3324/haematol.10699.CrossRefPubMed

33.

Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996, 42 (10): 1589-1600.PubMed

34.

Wicher KB, Fries E: Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like protein. PNAS. 2004, 101: 14390-14395. 10.1073/pnas.0405692101.PubMedCentralCrossRefPubMed

35.

Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J: Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol. 1984, 174: 343-368. 10.1016/0022-2836(84)90342-5.CrossRefPubMed

36.

Lange V: Haptoglobin polymorphism: not only a genetic marker. Anthropol Anz. 1992, 50: 281-302.PubMed

37.

Gutteridge JM: The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta. 1987, 917: 219-223.CrossRefPubMed

38.

Gogishvili AV, Kavtaradze VG, Mamaladze GT: Haptoglobin phenotype distribution in patients at high risk of developing myocardial infarct. Kardiologiia. 1985, 25: 55-58.PubMed

39.

Chapelle JP, Albert A, Smeets JP, Heusghem C, Kulbertus HE: Effect of the haptoglobin phenotype on the size of a myocardial infarct. N Engl J Med. 1982, 307: 457-463.CrossRefPubMed

40.

Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM: Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med. 2000, 343: 969-70. 10.1056/NEJM200009283431313.CrossRefPubMed

41.

Rantapãã Dahlqvist S, FrÖhlander N: Haptoglobin groups and rheumatoid arthritis. Hum Hered. 1985, 35: 207-11. 10.1159/000153546.CrossRef

42.

Rantapãã , Dahlqvist , Beckman G, Beckman L: Serum protein markers in systemic lupus erythematosus. Hum Hered. 1988, 38: 44-7. 10.1159/000153753.CrossRef

Title: Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation
Authors: Joseph McGuirk
Gang Hao
Weijian Hou
Sunil Abhyankar
Casey Williams
Weisi Yan
Jianda Yuan
Xiuqin Guan
Robert Belt
Shaun Dejarnette
Jeffery Wieman
Ying Yan
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2009
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-2-17

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

Lymphomatoid granulomatosis masquerading as interstitial pneumonia in a 66-year-old man: a case report and review of literature

R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature

RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression

Mechanism of action of lenalidomide in hematological malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer